Topics

Akebia and Otsuka Pharmaceutical Development & Commercialization Inc (OPDC) Announce Presentation of Four Posters at the NKF 2019 Spring Clinical Meetings

08:00 EDT 2 May 2019 | Businesswire
This article has expired, however you can still download the PDF.
Preview:
– Recent analyses highlight significant unmet clinical needs and burden of anemia due to chronic kidney disease Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and co...

Other Sources for this Article

Akebia Therapeutics:
Kristen K. Sheppard, Esq.
ir@akebia.com

Otsuka:
Otsuka In U.S.
Robert Murphy
Corporate Communications
Otsuka America Pharmaceutical, Inc.
robert.murphy@otsuka-us.com
609-249-7262

Otsuka Outside U.S.
Jeffrey Gilbert
Leader, Pharmaceutical PR
Otsuka Pharmaceutical, Co., Ltd.
gilbert.jeffrey@otsuka.co.jp
+81 3 6361 7379, +81 80 8728 6039

NEXT ARTICLE

More From BioPortfolio on "Akebia and Otsuka Pharmaceutical Development & Commercialization Inc (OPDC) Announce Presentation of Four Posters at the NKF 2019 Spring Clinical Meetings"

Quick Search

Relevant Topic

Nephrology - kidney function
Nephrology is a specialty of medicine and pediatrics that concerns itself with the study of normal kidney function, kidney problems, the treatment of kidney problems and renal replacement therapy (dialysis and kidney transplantation). Systemic conditions...